Current Status and Perspective of Development of Human <i>in vitro</i> Models for Prediction of Organ Toxicities in the Clinic

DOI Web Site
  • SAMESHIMA Tomoya
    武田薬品工業株式会社 リサーチ薬剤安全性研究所
  • OKAI Yoshiko
    武田薬品工業株式会社 リサーチ薬剤安全性研究所
  • KOHARA Hiroshi
    武田薬品工業株式会社 リサーチ薬剤安全性研究所
  • MATSUI Toshikatsu
    武田薬品工業株式会社 リサーチ薬剤安全性研究所
  • KIMURA Maya
    武田薬品工業株式会社 リサーチ薬剤安全性研究所
  • SHINOZAWA Tadahiro
    武田薬品工業株式会社 リサーチ薬剤安全性研究所

Bibliographic Information

Other Title
  • 臨床における臓器毒性予測を目指したヒト<i>in vitro</i>モデル開発の現状およびその展望
  • 臨床における臓器毒性予測を目指したヒトin vitroモデル開発の現状およびその展望
  • リンショウ ニ オケル ゾウキ ドクセイ ヨソク オ メザシタ ヒト in vitro モデル カイハツ ノ ゲンジョウ オヨビ ソノ テンボウ

Search this article

Description

<p>Despite recent advances in life sciences and large investment in drug discovery research, the success rate of drug development remains low. Since safety accounts for a large percentage of failure of clinical studies, selection of compounds with fewer toxicity concerns is the key to improving the success rate of drug development. However, predicting clinical toxicity from preclinical studies, which mainly use animal models, is still challenging because of species differences. Recently, in vitro models using human cells have been attracting attention to overcome this issue. These novel in vitro models have physiologically relevant functions compared to cell lines traditionally utilized in in vitro assays, thereby enabling us to predict toxicity in humans with high accuracy. Additionally, with the high throughput, these models can be applied from early stages of drug discovery research, thus making it possible to select more promising drug candidates and focus research and development resources on them. In this review, we introduce in vitro models to predict cardiotoxicity and hepatotoxicity, which are two leading causes of clinical failure derived from safety issues.</p>

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top